Press Releases

A team of US and European researchers have released new findings in Science Advances showing how the SARS-CoV-2 Spike (S)-protein interacts with human Estrogen Receptor Alpha (ERα) in lung tissue.
Data released as pre-print on bioRxiv reveals the interaction of SARS-CoV-2 (S) Spike proteins with ERα may increase the pro-coagulation activity of endothelial cells, enhancing the risk of thrombosis and shedding new light on the pathogenic mechanisms underlying SARS-CoV-2 infection and on its sex-specific differences.
Additional data by the same research groups highlights the mechanism underlying some rare vaccine-associated coagulopathies, which may be prevented by small changes in the Spike sequence used to produce currently available vaccines.

New Published Data Point to Spike Protein Interactions with Estrogen Receptors as a cause for Coagulopathy in Covid-19 Patients, Signaling Sex Effects and a Path to Improved Vaccines

Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants. Raloxifene was identified as a potential COVID-19 treatment by Exscalate4CoV consortium, a multidisciplinary European center of excellence created with the aim to fighting coronavirus by combining the best supercomputing resources and artificial intelligence
with state of the art experimental facilities up through clinical validation.New digital open tools for researches are now being developed with the support of the European High Performance Computing Joint Undertaking to further accelerate the drug discovery process.

Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé’s AI Platform for Drug Design

In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19).The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in patients with severe COVID-19 pneumonia.Results from the Phase 2 trial were presented at the American Thoracic Society (ATS) 2022 International Conference and published in Infectious Diseases and Therapy

Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia

Manuela Leone, MD and Whitney Hauser, OD join Dompé to Drive R&D and Medical Education Strategy

Dompé Further Elevates Commitment to Ophthalmics with Industry-Leading Hires

- Two Phase 3 multicenter clinical trials will evaluate the safety 
and efficacy of cenegermin in patients with severe Sjögren's-related dry
 eye disease- The Eye Research Foundation in Newport Beach, California is one of more than 10 clinical trial sites in the U.S. and Europe- Dompé is partnering with the Sjögren's Foundation to elevate 
understanding of the condition and provide information about 
opportunities to participate in clinical research.

Dompé announces first patient enrolled in Phase 3 trial of cenegermin in patients with severe Sjögren's-related dry eye disease

Dompé will provide access to its Exscalate AI drug discovery platform and drug discovery facilities, in exchange for milestones and royalties as part of a multi-year, multi-program strategic collaboration in fibrosis and liver-associated solid tumorsDompé farmaceutici is strategically investing in in Engitix’s $54m Series A financing co-led by existing investor Netherton Investments (a fund investing on behalf of Mike Platt) Gianluca Rossetti, Corporate Business Development Director at Dompé and Mike Platt, co-founder and Managing Director of BlueCrest Capital, to join Engitix board of directors

Dompé Farmaceutici S.P.A Announces Strategic Investment and Collaboration with Engitix Positioned Around Use of Dompé’s Exscalate Drug Discovery Platform

Dompé-Substipharm agreement for the sale of 6 brands

Phase 3 REP0220 multicenter clinical trial with 18 sites in the U.S. and Europe underway to determine whether treatment with reparixin, which inhibits the biological activity of IL-8 (CXCL-8), is effective in hospitalized patients with severe COVID-19 pneumonia Phase 2 REPAVID-19 trial results showed reparixin led to better management of respiratory distress when compared to standard of care1

Dompé Announces Activation of U.S. Clinical Trial Sites for Phase 3 Study of Reparixin, an Oral Investigational CXCR1/CXCR2 Inhibitor, in Hospitalized Patients with Severe COVID-19 Pneumonia

The core of the project is the aggregation of health data at a national level (from laboratory data to the genetic profile of the individual patient) with the highest safety standards (cyber security and real-time active protection) for targeted public health interventions and precision medicine.The newly-created infrastructure allows the clustering of patients’ profiles and the identification of targeted therapeutic indications through secure Cloud services, which are available to healthcare facilities throughout the country.The infrastructure leverages Davinci-1’s cloud computing – Leonardo’s High Performing Computer (HPC) – and Dompé Pharmaceuticals’ Exscalate molecular library – the enabler of the European Commission’s programme for Urgent Computing, Exscalate4Cov.

Leonardo and Dompé launch the first, national digital health security infrastructure with Cloud architecture

LIGATE will develop the leader software application for Drug Discovery exploiting today’s high-end supercomputer and tomorrow’s Exascale-acquired resources.The portable and tunable drug discovery platform will allow a drug discovery campaign in less than one day to respond promptly to worldwide pandemic such as that due to coronavirus. Following the successful results and data generated by EXSCALATE4COV[1]project, which identified some antiviral molecules and is testing one (raloxifene) in phase II/III clinical trials, LIGATE plans to publicly disclose to the scientific community also the result of a large experiment against immune resistant targets. LIGATE will run for a 3-year period with a total funding of €5.9 million, co-funded by European High-Performance Computing Joint Undertaking[2] (JU) with €2.6 million. [1]www.exscalate4cov.eu[2]https://eurohpc-ju.europa.eu

LIGATE: NEW EUROPEAN BACKED EFFORT AGAINST PANDEMICS KICKS OFF WITH 5,9 MLN €

- Pivotal study to assess whether treatment with Ladarixin, which inhibits the biological activity of IL-8, is effective in delaying the progression of T1D in adolescents and newly-diagnosed adults- First patient treated at Università Campus Bio-Medico di Roma, Rome, Italy; U.S. sites to follow in first half of 2021 

Dompé Announces First Patient Enrolled in Phase 3 trial of Ladarixin, an Oral Investigational CXCR1/2 Inhibitor, in New-Onset Type 1 Diabetes (T1D)

Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner to make their innovative product Oxervate™ (Cenegermin) available for patients affected by Neurotrophic Keratitis (NK) in Russia and other CIS countries.

DOMPÉ AND THE FARMAMONDO GROUP: EXCLUSIVE AGREEMENT TO DISTRIBUTE OXERVATE™ IN RUSSIA AND OTHER CIS COUNTRIES

DOMPÉ AND THE FARMAMONDO GROUP: EXSCLUSIVE AGREEMENT TO DISTRIBUTE OXERVATE™ IN RUSSIA AND OTHER CIS COUNTRIES

Footer

Who We Are

Science

Therapeutics

Manufacturing

Media

Contact

 Home

We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for “experience enhancement”, “measurement” and “targeting & advertising” as specified in the 

. Denying consent may make related features unavailable.

You can freely give, deny, or withdraw your consent at any time.

Use the “Accept” button to consent. Use the “Reject” button or close this notice to continue without accepting.